105 related articles for article (PubMed ID: 9378246)
21. Effect of 7-nitroindazole on tolerance to morphine, U-50,488H and [D-Pen2, D-Pen5] enkephalin in mice.
Bhargava HN; Cao YJ; Zhao GM
Peptides; 1997; 18(6):797-800. PubMed ID: 9285927
[TBL] [Abstract][Full Text] [Related]
22. Contralateral but not systemic administration of the kappa-opioid agonist U-50,488H induces anti-nociception in acute hindpaw inflammation in rats.
Bileviciute-Ljungar I; Spetea M
Br J Pharmacol; 2001 Jan; 132(1):252-8. PubMed ID: 11156584
[TBL] [Abstract][Full Text] [Related]
23. The effect of U-50,488H tolerance-dependence and abstinence on the levels of dynorphin (1-13) in brain regions, spinal cord, pituitary gland and peripheral tissues of the rat.
Bhargava HN; Matwyshyn GA; Rattan AK; Koo KL; Tejwani GA
Brain Res; 1993 Jan; 600(1):151-5. PubMed ID: 8093675
[TBL] [Abstract][Full Text] [Related]
24. Role of spinal kappa opioid receptors in the blockade of the development of antinociceptive tolerance to morphine.
Takahashi M; Senda T; Kaneto H
Eur J Pharmacol; 1991 Aug; 200(2-3):293-7. PubMed ID: 1664330
[TBL] [Abstract][Full Text] [Related]
25. Release by U-50,488H of [3H]serotonin from brain slices and spinal cord synaptosomes of U-50,488H-tolerant and nontolerant mice.
Ho BY; Takemori AE
J Pharmacol Exp Ther; 1990 Jul; 254(1):8-12. PubMed ID: 2164102
[TBL] [Abstract][Full Text] [Related]
26. Effects of U-50,488H and U-50,488H withdrawal on catecholaminergic neurons of the rat hypothalamus.
Laorden ML; Milanés MV
Life Sci; 2000 Jan; 66(9):803-15. PubMed ID: 10698355
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of a kappa-opioid receptor agonist-induced analgesia by L-tyrosine and L-tryptophan.
Barjavel MJ; Thorat SN; Bhargava HN
Eur J Pharmacol; 1994 Jun; 258(3):173-8. PubMed ID: 8088353
[TBL] [Abstract][Full Text] [Related]
28. Time course of the changes in central nitric oxide synthase activity following chronic treatment with morphine in the mouse: reversal by naltrexone.
Kumar S; Bhargava HN
Gen Pharmacol; 1997 Aug; 29(2):223-7. PubMed ID: 9251903
[TBL] [Abstract][Full Text] [Related]
29. Brain and spinal cord kappa opiate receptors and pharmacological responses to U-50,488H in rats of differing ages.
Bhargava HN; Matwyshyn GA; Reddy PL; Veeranna
Pharmacol Biochem Behav; 1994 May; 48(1):87-91. PubMed ID: 8029307
[TBL] [Abstract][Full Text] [Related]
30. Interactions of cocaine with morphine, U-50,488H and [D-Pen2, D-Pen5]enkaphalin.
Bhargava HN; Cao YJ
Peptides; 1998; 19(3):563-8. PubMed ID: 9533646
[TBL] [Abstract][Full Text] [Related]
31. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
Wilson JL; Nayanar V; Walker JS
Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
[TBL] [Abstract][Full Text] [Related]
32. Effects of histamine receptor antagonists injected intrathecally on antinociception induced by opioids administered intracerebroventricularly in the mouse.
Suh HW; Chung KM; Kim YH; Huh SO; Song DK
Neuropeptides; 1999 Apr; 33(2):121-9. PubMed ID: 10657481
[TBL] [Abstract][Full Text] [Related]
33. Long-term voluntary access to running wheels decreases kappa-opioid antinociception.
D'Anci KE; Gerstein AV; Kanarek RB
Pharmacol Biochem Behav; 2000 Jun; 66(2):343-6. PubMed ID: 10880688
[TBL] [Abstract][Full Text] [Related]
34. Serotonergic involvement in the antinociceptive action of and the development of tolerance to the kappa-opioid receptor agonist, U-50, 488H.
Ho BY; Takemori AE
J Pharmacol Exp Ther; 1989 Aug; 250(2):508-14. PubMed ID: 2547935
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of LY235959, a competitive antagonist of the NMDA receptor on kappa-opioid receptor agonist induced responses in mice and rats.
Bhargava HN; Thorat SN
Brain Res; 1997 Feb; 747(2):246-51. PubMed ID: 9045999
[TBL] [Abstract][Full Text] [Related]
36. Modulatory role of ginsenosides injected intrathecally or intracerebroventricularly in the production of antinociception induced by kappa-opioid receptor agonist administered intracerebroventricularly in the mouse.
Suh HW; Song DK; Huh SO; Kim YH
Planta Med; 2000 Jun; 66(5):412-7. PubMed ID: 10909259
[TBL] [Abstract][Full Text] [Related]
37. Effect of repeated administration of U-50,488H, a kappa opioid receptor agonist, on central 5-HT1 and 5-HT2 receptors in the rat.
Gulati A; Ramarao P; Bhargava HN
Pharmacology; 1989; 39(3):145-53. PubMed ID: 2587620
[TBL] [Abstract][Full Text] [Related]
38. Effects of U-50,488H, a kappa-opioid receptor agonist, on the learned helplessness model of depression in mice.
Ukai M; Suzuki M; Mamiya T
J Neural Transm (Vienna); 2002 Sep; 109(9):1221-5. PubMed ID: 12203050
[TBL] [Abstract][Full Text] [Related]
39. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
[TBL] [Abstract][Full Text] [Related]
40. U-50488H, a pure kappa receptor agonist with spinal analgesic loci in the mouse.
Piercey MF; Lahti RA; Schroeder LA; Einspahr FJ; Barsuhn C
Life Sci; 1982 Sep 20-27; 31(12-13):1197-200. PubMed ID: 6292608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
